



PROVIDING ANSWERS FOR CANCER PATIENTS

**Press release**  
**9 April, 2021**

## **Curasight A/S presents at Nordnet Live - Spotlight Small Cap investor conference 15 April 2021**

**Curasight A/S CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company and its future plans, at the Nordnet Live platform 15 April 2021, 16:20 (CET). The presentation will be webcasted live.**

**For more information and registration – please [click here](#)**

The event will be moderated by Brian Buus (Head of Business Management, Nordnet)

**For more information regarding Curasight, please contact:**

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: [uk@curasight.com](mailto:uk@curasight.com)

[www.curasight.com](http://www.curasight.com)

---

**Curasight** is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.